Pro-Dex (NASDAQ:PDEX) Receives New Coverage from Analysts at assumed coverage on shares of Pro-Dex (NASDAQ:PDEXGet Rating) in a research report report published on Monday morning. The firm issued a hold rating on the medical instruments supplier’s stock.

Separately, Ascendiant Capital Markets dropped their target price on Pro-Dex to $30.00 and set a na rating on the stock in a research report on Monday, May 16th.

Pro-Dex Trading Up 0.7 %

Shares of NASDAQ:PDEX opened at $16.01 on Monday. The company has a current ratio of 3.64, a quick ratio of 2.10 and a debt-to-equity ratio of 0.47. Pro-Dex has a 12-month low of $12.40 and a 12-month high of $32.00. The business has a 50 day moving average of $15.74 and a two-hundred day moving average of $17.17. The company has a market capitalization of $57.94 million, a PE ratio of 18.40 and a beta of 1.07.

Pro-Dex (NASDAQ:PDEXGet Rating) last posted its earnings results on Thursday, May 5th. The medical instruments supplier reported $0.12 earnings per share for the quarter. Pro-Dex had a net margin of 8.50% and a return on equity of 15.41%. The firm had revenue of $9.27 million during the quarter.

Institutional Investors Weigh In On Pro-Dex

A number of institutional investors have recently added to or reduced their stakes in PDEX. State Street Corp grew its position in shares of Pro-Dex by 5.8% in the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier’s stock valued at $197,000 after purchasing an additional 650 shares during the period. JPMorgan Chase & Co. lifted its holdings in Pro-Dex by 59.2% in the 1st quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier’s stock valued at $345,000 after purchasing an additional 7,762 shares in the last quarter. Finally, LSV Asset Management boosted its stake in Pro-Dex by 13.9% during the 1st quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock worth $588,000 after purchasing an additional 4,346 shares during the last quarter. Institutional investors and hedge funds own 16.73% of the company’s stock.

Pro-Dex Company Profile

(Get Rating)

Pro-Dex, Inc designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Featured Stories

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with's FREE daily email newsletter.